Grifols SA
No enriched coverage for $GRFS in the last 7 days.
No SEC Form 4 filings for $GRFS in the last 30 days.
Grifols (GRFS) is scheduled to release its Q1 2026 earnings on Thursday, April 30th, with analysts projecting $0.1731 EPS and $2.1247 billion in revenue. The company's earnings call is set for May 11, 2026. Institutional investors have significantly increased their stakes in Grifols, while Wall Street analysts have a mixed view, with an average "Reduce" rating and a $10.00 consensus price target.
Grifols (GRFS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols ( GRFS Quick QuoteGRFS - ) or Zoetis ( ZTS Quick QuoteZTS - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
